ODS-C study materials
ODS-C study resources

ODS-C: Cancer Registry Standards, Compliance, and Quality

ODS-C · Work through your exam, one topic at a time.

All guide sections

Cancer Registry Standards, Compliance, and Quality

Domain 3 - Cancer Registry Standards, Compliance, and Quality

This domain tests whether your registry meets external and internal rules: CoC accreditation standards, state mandates, NAACCR and STORE conventions, and quality benchmarks.

Core rules

  • Standards hierarchy: state law and reporting requirements, CoC standards, NAACCR data standards, and facility policy. When they conflict, follow the stricter applicable requirement and document the decision.
  • CoC accreditation requires a functioning registry, cancer committee, cancer conference, quality improvement activity, and timely NCDB data submission.
  • Data quality dimensions: completeness, accuracy, timeliness, and consistency. Monitor each with casefinding audits, reabstracting audits, edit checks, and follow-up reviews.
  • NAACCR edits catch impossible or inconsistent values; resolve them rather than overriding without reason.
  • Confidentiality: HIPAA permits treatment, payment, operations, and public-health reporting. Release only the minimum necessary data and follow state registry agreements.
  • Follow-up must be active and documented; lost-to-follow-up status is not a substitute for outreach.

Worked example

A reabstracting audit reviews 20 analytic cases against source documents. Three have incorrect stage or treatment fields, a 15% error rate. Reasoning: the registry's quality plan commonly targets a major error rate of 5% or less. The registrar documents each discrepancy, corrects the abstracts, and performs focused re-education on staging rules. The result is reported to the cancer committee as a quality improvement project.

Traps

  • Treating an edit override as a fix.
  • Submitting to the state but missing the NCDB deadline.
  • Assuming state reporting law satisfies CoC requirements.
  • Counting a 'no evidence of disease' note as complete follow-up without a date.